{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T14:26:42Z","timestamp":1793111202897,"version":"4.5.0"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"27","license":[{"start":{"date-parts":[[2021,6,14]],"date-time":"2021-06-14T00:00:00Z","timestamp":1623628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2021,6,14]],"date-time":"2021-06-14T00:00:00Z","timestamp":1623628800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["CA174798"],"award-info":[{"award-number":["CA174798"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["5P50 CA140388"],"award-info":[{"award-number":["5P50 CA140388"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["P30 CA16672"],"award-info":[{"award-number":["P30 CA16672"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute"},{"name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Oncogene"],"published-print":{"date-parts":[[2021,7,8]]},"DOI":"10.1038\/s41388-021-01874-7","type":"journal-article","created":{"date-parts":[[2021,6,14]],"date-time":"2021-06-14T21:02:39Z","timestamp":1623704559000},"page":"4592-4603","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Statins reduce castration-induced bone marrow adiposity and prostate cancer progression in bone"],"prefix":"10.1038","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6891-2063","authenticated-orcid":false,"given":"Tianhong","family":"Pan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Song-Chang","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Chen","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guoyu","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian H.","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Titus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert L.","family":"Satcher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theocharis","family":"Panaretakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Logothetis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-Yuan","family":"Yu-Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6122-4054","authenticated-orcid":false,"given":"Sue-Hwa","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,6,14]]},"reference":[{"key":"1874_CR1","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1038\/nrc4016","volume":"15","author":"PA Watson","year":"2015","unstructured":"Watson PA, Arora VK, Sawyers CL. Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer. Nat Rev Cancer. 2015;15:701\u201311.","journal-title":"Nat Rev Cancer"},{"key":"1874_CR2","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1056\/NEJMra030831","volume":"350","author":"GD Roodman","year":"2004","unstructured":"Roodman GD. Mechanisms of bone metastasis. N Engl J Med. 2004;350:1655\u201364.","journal-title":"N Engl J Med"},{"key":"1874_CR3","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1158\/2159-8290.CD-12-0460","volume":"3","author":"CJ Logothetis","year":"2013","unstructured":"Logothetis CJ, Gallick GE, Maity SN, Kim J, Aparicio A, Efstathiou E, et al. Molecular classification of prostate cancer progression: foundation for marker-driven treatment of prostate cancer. Cancer Discov. 2013;3:849\u201361.","journal-title":"Cancer Discov"},{"key":"1874_CR4","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.1093\/jnci\/djj499","volume":"98","author":"EA Platz","year":"2006","unstructured":"Platz EA, Leitzmann MF, Visvanathan K, Rimm EB, Stampfer MJ, Willett WC, et al. Statin drugs and risk of advanced prostate cancer. J Natl Cancer Inst. 2006;98:1819\u201325.","journal-title":"J Natl Cancer Inst"},{"key":"1874_CR5","doi-asserted-by":"publisher","first-page":"19861","DOI":"10.18632\/oncotarget.24888","volume":"9","author":"JA Gordon","year":"2018","unstructured":"Gordon JA, Buonerba C, Pond G, Crona D, Gillessen S, Lucarelli G, et al. Statin use and survival in patients with metastatic castration-resistant prostate cancer treated with abiraterone or enzalutamide after docetaxel failure: the international retrospective observational STABEN study. Oncotarget. 2018;9:19861\u201373.","journal-title":"Oncotarget"},{"key":"1874_CR6","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1001\/jamaoncol.2015.0829","volume":"1","author":"LC Harshman","year":"2015","unstructured":"Harshman LC, Wang X, Nakabayashi M, Xie W, Valenca L, Werner L, et al. Statin use at the time of initiation of androgen deprivation therapy and time to progression in patients with hormone-sensitive prostate cancer. JAMA Oncol. 2015;1:495\u2013504.","journal-title":"JAMA Oncol"},{"key":"1874_CR7","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1038\/nrurol.2016.199","volume":"14","author":"MA Alfaqih","year":"2017","unstructured":"Alfaqih MA, Allott EH, Hamilton RJ, Freeman MR, Freedland SJ. The current evidence on statin use and prostate cancer prevention: are we there yet? Nat Rev Urol. 2017;14:107\u201319.","journal-title":"Nat Rev Urol"},{"key":"1874_CR8","doi-asserted-by":"publisher","first-page":"4949","DOI":"10.1158\/0008-5472.CAN-15-1215","volume":"75","author":"YC Lee","year":"2015","unstructured":"Lee YC, Lin SC, Yu G, Cheng CJ, Liu B, Liu HC, et al. Identification of bone-derived factors conferring de novo therapeutic resistance in metastatic prostate cancer. Cancer Res. 2015;75:4949\u201359.","journal-title":"Cancer Res"},{"key":"1874_CR9","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1038\/nrc1528","volume":"5","author":"C Logothetis","year":"2005","unstructured":"Logothetis C, Lin S-H. Osteoblasts in prostate cancer metastasis to bone. Nat Rev Cancer. 2005;5:21\u20138.","journal-title":"Nat Rev Cancer"},{"key":"1874_CR10","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.1182\/blood-2015-07-533588","volume":"126","author":"LM Calvi","year":"2015","unstructured":"Calvi LM, Link DC. The hematopoietic stem cell niche in homeostasis and disease. Blood. 2015;126:2443\u201351.","journal-title":"Blood"},{"key":"1874_CR11","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1515\/hmbci-2014-0045","volume":"21","author":"J Diedrich","year":"2015","unstructured":"Diedrich J, Gusky HC, Podgorski I. Adipose tissue dysfunction and its effects on tumor metabolism. Horm Mol Biol Clin Investig. 2015;21:17\u201341.","journal-title":"Horm Mol Biol Clin Investig"},{"key":"1874_CR12","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.18632\/oncotarget.1482","volume":"4","author":"MK Herroon","year":"2013","unstructured":"Herroon MK, Rajagurubandara E, Hardaway AL, Powell K, Turchick A, Feldmann D, et al. Bone marrow adipocytes promote tumor growth in bone via FABP4-dependent mechanisms. Oncotarget. 2013;4:2108\u201323.","journal-title":"Oncotarget"},{"key":"1874_CR13","doi-asserted-by":"publisher","first-page":"R305","DOI":"10.1677\/ERC-10-0187","volume":"17","author":"N Sharifi","year":"2010","unstructured":"Sharifi N, Gulley JL, Dahut WL. An update on androgen deprivation therapy for prostate cancer. Endocr Relat Cancer. 2010;17:R305\u201315.","journal-title":"Endocr Relat Cancer"},{"key":"1874_CR14","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1016\/S8756-3282(96)00258-X","volume":"19","author":"JM Gimble","year":"1996","unstructured":"Gimble JM, Robinson CE, Wu X, Kelly KA. The function of adipocytes in the bone marrow stroma: an update. Bone. 1996;19:421\u20138.","journal-title":"Bone"},{"key":"1874_CR15","doi-asserted-by":"publisher","first-page":"127","DOI":"10.3389\/fendo.2016.00127","volume":"7","author":"M Tencerova","year":"2016","unstructured":"Tencerova M, Kassem M. The bone marrow-derived stromal cells: commitment and regulation of adipogenesis. Front Endocrinol (Lausanne). 2016;7:127.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"1874_CR16","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1182\/blood.V78.3.666.666","volume":"78","author":"HJ Sutherland","year":"1991","unstructured":"Sutherland HJ, Eaves CJ, Lansdorp PM, Thacker JD, Hogge DE. Differential regulation of primitive human hematopoietic cells in long-term cultures maintained on genetically engineered murine stromal cells. Blood. 1991;78:666\u201372.","journal-title":"Blood"},{"key":"1874_CR17","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1042\/CS20170090","volume":"131","author":"AK Lucas-Herald","year":"2017","unstructured":"Lucas-Herald AK, Alves-Lopes R, Montezano AC, Ahmed SF, Touyz RM. Genomic and non-genomic effects of androgens in the cardiovascular system: clinical implications. Clin Sci (Lond). 2017;131:1405\u201318.","journal-title":"Clin Sci (Lond)"},{"key":"1874_CR18","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2017.510","volume":"8","author":"D Lin","year":"2017","unstructured":"Lin D, Alberton P, Caceres MD, Volkmer E, Schieker M, Docheva D. Tenomodulin is essential for prevention of adipocyte accumulation and fibrovascular scar formation during early tendon healing. Cell Death Dis. 2017;8:e3116.","journal-title":"Cell Death Dis"},{"key":"1874_CR19","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1007\/s10038-003-0103-6","volume":"49","author":"K Sato","year":"2004","unstructured":"Sato K, Emi M, Ezura Y, Fujita Y, Takada D, Ishigami T, et al. Soluble epoxide hydrolase variant (Glu287Arg) modifies plasma total cholesterol and triglyceride phenotype in familial hypercholesterolemia: intrafamilial association study in an eight-generation hyperlipidemic kindred. J Hum Genet. 2004;49:29\u201334.","journal-title":"J Hum Genet"},{"key":"1874_CR20","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/j.cell.2007.12.033","volume":"132","author":"A Sakaue-Sawano","year":"2008","unstructured":"Sakaue-Sawano A, Kurokawa H, Morimura T, Hanyu A, Hama H, Osawa H, et al. Visualizing spatiotemporal dynamics of multicellular cell-cycle progression. Cell. 2008;132:487\u201398.","journal-title":"Cell"},{"key":"1874_CR21","doi-asserted-by":"publisher","first-page":"13316","DOI":"10.1074\/jbc.M609798200","volume":"282","author":"NK Saxena","year":"2007","unstructured":"Saxena NK, Vertino PM, Anania FA, Sharma D. leptin-induced growth stimulation of breast cancer cells involves recruitment of histone acetyltransferases and mediator complex to CYCLIN D1 promoter via activation of Stat3. J Biol Chem. 2007;282:13316\u201325.","journal-title":"J Biol Chem"},{"key":"1874_CR22","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1007\/s10557-019-06904-x","volume":"33","author":"V Azemawah","year":"2019","unstructured":"Azemawah V, Movahed MR, Centuori P, Penaflor R, Riel PL, Situ S, et al. State of the art comprehensive review of individual statins, their differences, pharmacology, and clinical implications. Cardiovasc Drugs Ther. 2019;33:625\u201339.","journal-title":"Cardiovasc Drugs Ther"},{"key":"1874_CR23","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1042\/BJ20101939","volume":"438","author":"T Goto","year":"2011","unstructured":"Goto T, Nagai H, Egawa K, Kim YI, Kato S, Taimatsu A, et al. Farnesyl pyrophosphate regulates adipocyte functions as an endogenous PPARgamma agonist. Biochem J. 2011;438:111\u20139.","journal-title":"Biochem J"},{"key":"1874_CR24","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1002\/pros.23479","volume":"78","author":"L Xu","year":"2018","unstructured":"Xu L, Shen M, Chen X, Zhu R, Yang DR, Tsai Y, et al. Adipocytes affect castration-resistant prostate cancer cells to develop the resistance to cytotoxic action of NK cells with alterations of PD-L1\/NKG2D ligand levels in tumor cells. Prostate. 2018;78:353\u201364.","journal-title":"Prostate"},{"key":"1874_CR25","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms10230","volume":"7","author":"V Laurent","year":"2016","unstructured":"Laurent V, Guerard A, Mazerolles C, Le Gonidec S, Toulet A, Nieto L, et al. Periprostatic adipocytes act as a driving force for prostate cancer progression in obesity. Nat Commun. 2016;7:10230.","journal-title":"Nat Commun"},{"key":"1874_CR26","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1158\/1541-7786.MCR-18-0748","volume":"17","author":"V Laurent","year":"2019","unstructured":"Laurent V, Toulet A, Attane C, Milhas D, Dauvillier S, Zaidi F, et al. Periprostatic adipose tissue favors prostate cancer cell invasion in an obesity-dependent manner: role of oxidative stress. Mol Cancer Res. 2019;17:821\u201335.","journal-title":"Mol Cancer Res"},{"key":"1874_CR27","doi-asserted-by":"publisher","first-page":"4939","DOI":"10.18632\/oncotarget.6643","volume":"7","author":"KD Tang","year":"2016","unstructured":"Tang KD, Liu J, Jovanovic L, An J, Hill MM, Vela I, et al. Adipocytes promote prostate cancer stem cell self-renewal through amplification of the cholecystokinin autocrine loop. Oncotarget. 2016;7:4939\u201348.","journal-title":"Oncotarget"},{"key":"1874_CR28","doi-asserted-by":"publisher","first-page":"64854","DOI":"10.18632\/oncotarget.11712","volume":"7","author":"JD Diedrich","year":"2016","unstructured":"Diedrich JD, Rajagurubandara E, Herroon MK, Mahapatra G, Huttemann M, Podgorski I. Bone marrow adipocytes promote the Warburg phenotype in metastatic prostate tumors via HIF-1alpha activation. Oncotarget. 2016;7:64854\u201377.","journal-title":"Oncotarget"},{"key":"1874_CR29","first-page":"189","volume":"98","author":"M Tavassoli","year":"1974","unstructured":"Tavassoli M. Marrow adipose cells. Ultrastructural and histochemical characterization. Arch Pathol. 1974;98:189\u201392.","journal-title":"Arch Pathol"},{"key":"1874_CR30","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1159\/000144545","volume":"94","author":"M Tavassoli","year":"1976","unstructured":"Tavassoli M. Ultrastructural development of bone marrow adipose cell. Acta Anat (Basel). 1976;94:65\u201377.","journal-title":"Acta Anat (Basel)"},{"key":"1874_CR31","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1038\/sj.leu.2404658","volume":"21","author":"J Caers","year":"2007","unstructured":"Caers J, Deleu S, Belaid Z, De Raeve H, Van Valckenborgh E, De Bruyne E, et al. Neighboring adipocytes participate in the bone marrow microenvironment of multiple myeloma cells. Leukemia. 2007;21:1580\u20134.","journal-title":"Leukemia"},{"key":"1874_CR32","doi-asserted-by":"publisher","first-page":"34329","DOI":"10.18632\/oncotarget.6020","volume":"6","author":"Z Liu","year":"2015","unstructured":"Liu Z, Xu J, He J, Liu H, Lin P, Wan X, et al. Mature adipocytes in bone marrow protect myeloma cells against chemotherapy through autophagy activation. Oncotarget. 2015;6:34329\u201341.","journal-title":"Oncotarget"},{"key":"1874_CR33","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1007\/s10555-013-9484-y","volume":"33","author":"AL Hardaway","year":"2014","unstructured":"Hardaway AL, Herroon MK, Rajagurubandara E, Podgorski I. Bone marrow fat: linking adipocyte-induced inflammation with skeletal metastases. Cancer Metastasis Rev. 2014;33:527\u201343.","journal-title":"Cancer Metastasis Rev"},{"key":"1874_CR34","doi-asserted-by":"publisher","first-page":"9159","DOI":"10.1002\/jcp.26884","volume":"233","author":"EV Morris","year":"2018","unstructured":"Morris EV, Edwards CM. Adipokines, adiposity, and bone marrow adipocytes: dangerous accomplices in multiple myeloma. J Cell Physiol. 2018;233:9159\u201366.","journal-title":"J Cell Physiol"},{"key":"1874_CR35","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1007\/s10585-015-9714-5","volume":"32","author":"AL Hardaway","year":"2015","unstructured":"Hardaway AL, Herroon MK, Rajagurubandara E, Podgorski I. Marrow adipocyte-derived CXCL1 and CXCL2 contribute to osteolysis in metastatic prostate cancer. Clin Exp Metastasis. 2015;32:353\u201368.","journal-title":"Clin Exp Metastasis"},{"key":"1874_CR36","doi-asserted-by":"publisher","first-page":"3493","DOI":"10.1210\/jcem.82.10.4319","volume":"82","author":"EO Abu","year":"1997","unstructured":"Abu EO, Horner A, Kusec V, Triffitt JT, Compston JE. The localization of androgen receptors in human bone. J Clin Endocrinol Metab. 1997;82:3493\u20137.","journal-title":"J Clin Endocrinol Metab"},{"key":"1874_CR37","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1002\/1096-9896(0000)9999:9999<::AID-PATH803>3.0.CO;2-W","volume":"193","author":"A Mantalaris","year":"2001","unstructured":"Mantalaris A, Panoskaltsis N, Sakai Y, Bourne P, Chang C, Messing EM, et al. Localization of androgen receptor expression in human bone marrow. J Pathol. 2001;193:361\u20136.","journal-title":"J Pathol"},{"key":"1874_CR38","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1677\/ERC-10-0059","volume":"17","author":"S Crnalic","year":"2010","unstructured":"Crnalic S, Hornberg E, Wikstrom P, Lerner UH, Tieva A, Svensson O, et al. Nuclear androgen receptor staining in bone metastases is related to a poor outcome in prostate cancer patients. Endocr Relat Cancer. 2010;17:885\u201395.","journal-title":"Endocr Relat Cancer"},{"key":"1874_CR39","first-page":"E6039","volume":"115","author":"Y Zhang","year":"2018","unstructured":"Zhang Y, Dallner OS, Nakadai T, Fayzikhodjaeva G, Lu YH, Lazar MA, et al. A noncanonical PPARgamma\/RXRalpha-binding sequence regulates leptin expression in response to changes in adipose tissue mass. Proc Natl Acad Sci USA. 2018;115:E6039\u2013E6047.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1874_CR40","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1530\/ERC-14-0199","volume":"21","author":"PD Ottewell","year":"2014","unstructured":"Ottewell PD, Wang N, Meek J, Fowles CA, Croucher PI, Eaton CL, et al. Castration-induced bone loss triggers growth of disseminated prostate cancer cells in bone. Endocr Relat Cancer. 2014;21:769\u201381.","journal-title":"Endocr Relat Cancer"},{"key":"1874_CR41","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1111\/j.1349-7006.2007.00690.x","volume":"99","author":"S Sato","year":"2008","unstructured":"Sato S, Futakuchi M, Ogawa K, Asamoto M, Nakao K, Asai K, et al. Transforming growth factor beta derived from bone matrix promotes cell proliferation of prostate cancer and osteoclast activation-associated osteolysis in the bone microenvironment. Cancer Sci. 2008;99:316\u201323.","journal-title":"Cancer Sci"},{"key":"1874_CR42","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1016\/j.cell.2019.10.029","volume":"179","author":"S Jiao","year":"2019","unstructured":"Jiao S, Subudhi SK, Aparicio A, Ge Z, Guan B, Miura Y, et al. Differences in tumor microenvironment dictate T helper lineage polarization and response to immune checkpoint therapy. Cell. 2019;179:1177\u201390.e13.","journal-title":"Cell"},{"key":"1874_CR43","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1002\/(SICI)1097-0215(19980911)77:6<887::AID-IJC15>3.0.CO;2-Z","volume":"77","author":"TT Wu","year":"1998","unstructured":"Wu TT, Sikes RA, Cui Q, Thalmann GN, Kao C, Murphy CF, et al. Establishing human prostate cancer cell xenografts in bone: induction of osteoblastic reaction by prostate-specific antigen-producing tumors in athymic and SCID\/bg mice using LNCaP and lineage-derived metastatic sublines. Int J Cancer. 1998;77:887\u201394.","journal-title":"Int J Cancer"},{"key":"1874_CR44","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1002\/1097-0045(20000701)44:2<91::AID-PROS1>3.0.CO;2-L","volume":"44","author":"GN Thalmann","year":"2000","unstructured":"Thalmann GN, Sikes RA, Wu TT, Degeorges A, Chang SM, Ozen M, et al. LNCaP progression model of human prostate cancer: androgen-independence and osseous metastasis. Prostate. 2000;44:91\u2013103.","journal-title":"Prostate"},{"key":"1874_CR45","first-page":"2577","volume":"54","author":"GN Thalmann","year":"1994","unstructured":"Thalmann GN, Anezinis PE, Chang S, Zhau HE, Kim E, Hopwood VL, et al. Androgen-independent cancer progression and bone metastasis in the LNCaP model of human prostate cancer. Cancer Res. 1994;54:2577\u201381.","journal-title":"Cancer Res"},{"key":"1874_CR46","first-page":"6049","volume":"54","author":"MA Wainstein","year":"1994","unstructured":"Wainstein MA, He F, Robinson D, Kung HJ, Schwartz S, Giaconia JM, et al. CWR22: androgen-dependent xenograft model derived from a primary human prostatic carcinoma. Cancer Res. 1994;54:6049\u201352.","journal-title":"Cancer Res"},{"key":"1874_CR47","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1007\/s11626-999-0115-4","volume":"35","author":"RM Sramkoski","year":"1999","unstructured":"Sramkoski RM, Pretlow TG 2nd, Giaconia JM, Pretlow TP, Schwartz S, Sy MS, et al. A new human prostate carcinoma cell line, 22Rv1. In Vitro Cell Dev Biol Anim. 1999;35:403\u20139.","journal-title":"In Vitro Cell Dev Biol Anim"},{"key":"1874_CR48","doi-asserted-by":"publisher","first-page":"2911","DOI":"10.1158\/0008-5472.CAN-17-1051","volume":"78","author":"LY Yu-Lee","year":"2018","unstructured":"Yu-Lee LY, Yu G, Lee YC, Lin SC, Pan J, Pan T, et al. Osteoblast-secreted factors mediate dormancy of metastatic prostate cancer in the bone via activation of the TGFbetaRIII-p38MAPK-pS249\/T252RB pathway. Cancer Res. 2018;78:2911\u201324.","journal-title":"Cancer Res"},{"key":"1874_CR49","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1158\/1541-7786.MCR-12-0551","volume":"11","author":"YC Lee","year":"2013","unstructured":"Lee YC, Jin JK, Cheng CJ, Huang CF, Song JH, Huang M, et al. Targeting constitutively activated beta1 integrins inhibits prostate cancer metastasis. Mol Cancer Res. 2013;11:405\u201317.","journal-title":"Mol Cancer Res"}],"container-title":["Oncogene"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41388-021-01874-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41388-021-01874-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41388-021-01874-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,4]],"date-time":"2023-11-04T21:59:34Z","timestamp":1699135174000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41388-021-01874-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,14]]},"references-count":49,"journal-issue":{"issue":"27","published-print":{"date-parts":[[2021,7,8]]}},"alternative-id":["1874"],"URL":"https:\/\/doi.org\/10.1038\/s41388-021-01874-7","relation":{},"ISSN":["0950-9232","1476-5594"],"issn-type":[{"value":"0950-9232","type":"print"},{"value":"1476-5594","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,14]]},"assertion":[{"value":"19 February 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 May 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 May 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 June 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"C.L. reports receiving commercial research grants from Bayer, Sanofi, Janssen, Astellas Pharma, Pfizer; and honoraria from Bayer, Janssen, Sanofi, Astellas Pharma. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}